HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives $20.88 Consensus PT from Brokerages

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) has received a consensus recommendation of “Hold” from the six research firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, one has assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $20.8750.

Several research firms recently commented on HCM. Weiss Ratings reiterated a “hold (c)” rating on shares of HUTCHMED in a report on Thursday, January 22nd. Jefferies Financial Group raised shares of HUTCHMED to a “strong-buy” rating in a report on Monday, January 19th. Finally, Wall Street Zen upgraded shares of HUTCHMED from a “hold” rating to a “buy” rating in a research note on Sunday, November 16th.

Institutional Investors Weigh In On HUTCHMED

Hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC boosted its stake in shares of HUTCHMED by 128.0% in the 1st quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock worth $3,343,000 after buying an additional 124,771 shares during the last quarter. UBS Group AG lifted its holdings in HUTCHMED by 112.8% in the third quarter. UBS Group AG now owns 137,000 shares of the company’s stock valued at $2,158,000 after acquiring an additional 72,614 shares during the period. Amundi boosted its position in HUTCHMED by 41.9% in the third quarter. Amundi now owns 223,330 shares of the company’s stock worth $3,620,000 after purchasing an additional 65,898 shares during the last quarter. ABN Amro Investment Solutions purchased a new position in HUTCHMED in the second quarter worth about $962,000. Finally, M&G PLC grew its stake in shares of HUTCHMED by 26.7% during the 4th quarter. M&G PLC now owns 259,033 shares of the company’s stock valued at $3,367,000 after purchasing an additional 54,601 shares during the period. 8.82% of the stock is currently owned by hedge funds and other institutional investors.

HUTCHMED Trading Up 1.3%

HUTCHMED stock opened at $13.65 on Monday. HUTCHMED has a 12 month low of $11.51 and a 12 month high of $19.50. The stock has a fifty day simple moving average of $14.70 and a two-hundred day simple moving average of $15.00. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.65 and a quick ratio of 4.51.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.